Oncology

Report uncovers variations in diagnosis and treatment across Canada

Pauses in prostate cancer treatment give patients relief from side-effects

Two-drug combo looks promising in phase II trial

Six months of treatment may be worse and two years is no better

‘Integrative oncology’ gets government funding, but alarms skeptical physicians

TORONTO | Canadian efforts to reduce the burden of breast cancer—the most commonly diagnosed cancer and second leading cause of cancer death among Canadian women— will soon benefit from a new resource.

Drug indicated for treatment of patients with relapsed indolent B-cell non-Hodgkin lymphoma.